Y mAbs Therapeutics - Asset Resilience Ratio

Latest as of September 2018: 0.02%

Y mAbs Therapeutics (YMAB) has an Asset Resilience Ratio of 0.02% as of September 2018. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check YMAB PP&E to net assets ratio to assess the company's strategic physical and investment asset allocation.

Liquid Assets

$31.00K

Cash + Short-term Investments

Total Assets

$166.39 Million

All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2017)

This chart shows how Y mAbs Therapeutics's Asset Resilience Ratio has changed over time. See how leveraged is Y mAbs Therapeutics's balance sheet to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Y mAbs Therapeutics's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Y mAbs Therapeutics (YMAB) total market value.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	$0.00	0%
Short-term Investments	$31.00K	0.02%
Total Liquid Assets	$31.00K	0.02%

Asset Resilience Insights

Limited Liquidity: Y mAbs Therapeutics maintains only 0.02% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Y mAbs Therapeutics Industry Peers by Asset Resilience Ratio

Compare Y mAbs Therapeutics's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	0.00%
Cyclacel Pharmaceuticals Inc NASDAQ:CYCC	Biotechnology	-55.36%
Krystal Biotech Inc NASDAQ:KRYS	Biotechnology	23.06%
Verona Pharma PLC ADR NASDAQ:VRNA	Biotechnology	0.00%
Centessa Pharmaceuticals PLC ADR NASDAQ:CNTA	Biotechnology	33.37%
Beijing Tiantan Biological Products Corp Ltd SHG:600161	Biotechnology	8.08%
Hebei Changshan Biochem Pharma SHE:300255	Biotechnology	-0.03%
BB Biotech AG SW:BION	Biotechnology	0.05%

Annual Asset Resilience Ratio for Y mAbs Therapeutics (2016–2017)

The table below shows the annual Asset Resilience Ratio data for Y mAbs Therapeutics.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2017-12-31	0.03%	$32.00K	$92.13 Million	-0.13pp
2016-12-31	0.16%	$28.00K	$17.26 Million	--

pp = percentage points

About Y mAbs Therapeutics

NASDAQ:YMAB USA Biotechnology

Market Cap

$391.22 Million

Market Cap Rank

#13671 Global

#3239 in USA

Share Price

$8.61

Change (1 day)

+0.23%

52-Week Range

$4.19 - $8.61

All Time High

$54.26